- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03135873
Mastiha Treatment for Obese With NAFLD Diagnosis (MAST4HEALTH)
April 6, 2022 updated by: Andriana C Kaliora, Harokopio University
NAFLD/NASH is one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients.
Due to the lack of specialized treatment, many new efforts focus on exploring alternative, non-pharmacologic means for managing the disease, including bioactive substances in fruits, vegetables and plants or their products.
Mastiha, a natural product of Greece, consists of a great variety of bioactive phytochemical compounds and demonstrates antioxidant, antiinflammatory, antimicrobial and lipid lowering properties.
Taking into account the contribution of oxidative stress and inflammation to NAFLD/NASH pathogenesis, the hypothesis that Mastiha could improve disease aspects is investigated.
Thus, design of a multicenter (4 centers across Europe), randomized, double-blind, placebo controlled (parallel arm) clinical trial to assess the effect of Mastiha on clinical course of NAFLD/NASH patients has been conducted.
The effectiveness of the proposed intervention will be evaluated via clinical and laboratory markers.
MAST4HEALTH aims also at exploring gene-diet interactions and at correlating genetic and epigenetic markers with metabolomic and intestinal microbiota profiles pre- and post- intervention.
To this end, patients with confirmed NAFLD/NASH will be allocated to either verum or placebo group.
Duration of the intervention will be 6 months and the dosage applied will be 2.1 g daily.
NAFLD/NASH diagnosis will be confirmed by MS scanning and the sensitive LiverMultiScan technique.
Anthropometric, demographic data, body composition, dietary habits, physical activity, family history and smoking status will be assessed pre- and post- intervention.
Biochemical profile, oxidative stress and inflammation, as well as epigenetic and metabolomic profiles will be assessed in blood samples, while the metagenome profile will be examined in stools.
Both groups will receive counselling to allow for body weight regulation up to 5%.
Compliance will be assessed monthly and side effects will be reported.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Attica
-
Athens, Attica, Greece, 17671
- Harokopio University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 67 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed NAFLD/NASH
- 18 years < Age < 67 years
- BMI > 30 kg/ m2
Exclusion Criteria:
- Hepatotoxic Medication, Concomitant Liver Disease
- Decompensated Diabetes Mellitus
- Dysthyroidism, hypopituitarism, Cushing syndrome / disease
- Alcohol abuse or drug addiction
- Clinically or biochemically recognized systemic diseases
- Pregnancy test, lactation
- Vegan or lacto- and ovo-lacto- vegetarianism
- Psychiatric or mental disorder
- Recent loss in body weight or current diet
- Any use of antioxidant-phytochemical rich supplement, anti-, pre- or pro-biotics within 3 months pre-intervention
- Changes in drug treatment for e.g. hypertension, diabetes mellitus, 3 months prior or during the 6month intervention
- Antibiotic treatment during and 2 months prior to screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Mastiha
This arm of patients will receive natural Mastiha supplements at a daily dosage of 2.1 g for a 6 month period.
|
Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).
|
PLACEBO_COMPARATOR: Placebo
This arm of patients will receive placebo for a 6 month period.
|
Placebo is designed to have identical characteristics with verum.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LIF score
Time Frame: 6 months
|
Improvement in liver histopathology reflected in reduction of the sensitive LIF score
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NAFLD/NASH-related laboratory markers
Time Frame: 6 months
|
Liver enzymes improvement, inflammation and oxidative stress markers improvement (e.g.
IL-6, IL-10, TNF-α, GSH, Gpx), lipid profile improvement, insulin sensitivity improvement pre- and post- intervention in each intervention arm.
|
6 months
|
Anthropometric characteristics
Time Frame: 6 months
|
BMI pre- and post- intervention in each intervention arm.
|
6 months
|
Genetic profile
Time Frame: 6 months
|
Profiles with a comprehensive set of genetic variants to look for markers implicated in response to Mastiha treatment.
|
6 months
|
Metabolomic profile
Time Frame: 6 months
|
Quantification of endogenous metabolites from different compound classes
|
6 months
|
Metagenomic profile
Time Frame: 6 months
|
Association of gut microbes with Mastiha treatment in NAFLD
|
6 months
|
Epigenetic profile
Time Frame: 6 months
|
Identification of the subset of variably methylated regions with low within-individual variability over the six months period of the study to correlate them to treatment.
|
6 months
|
Effect of Mastiha on different BMI categories
Time Frame: 6 months
|
Identification of the effect of Mastiha on different obesity categories: Class I obesity (BMI ≤ 35) and Class II or III obesity (BMI> 35)
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: G V DEDOUSIS, PROF., Harokopio University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014 Jan;60(1):69-77. doi: 10.1016/j.jhep.2013.09.002. Epub 2013 Sep 12.
- Abenavoli L, Milic N, Di Renzo L, Preveden T, Medic-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2016 Aug 21;22(31):7006-16. doi: 10.3748/wjg.v22.i31.7006.
- Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, Collier J, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016 Feb;64(2):308-315. doi: 10.1016/j.jhep.2015.10.009. Epub 2015 Nov 10.
- Hassan K, Bhalla V, El Regal ME, A-Kader HH. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol. 2014 Sep 14;20(34):12082-101. doi: 10.3748/wjg.v20.i34.12082.
- Yao H, Qiao YJ, Zhao YL, Tao XF, Xu LN, Yin LH, Qi Y, Peng JY. Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol. 2016 Aug 14;22(30):6890-905. doi: 10.3748/wjg.v22.i30.6890.
- Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int. 2015;2015:460190. doi: 10.1155/2015/460190. Epub 2015 Jul 27.
- Fan JG, Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:81-7. doi: 10.1111/jgh.12244.
- Triantafyllou A, Chaviaras N, Sergentanis TN, Protopapa E, Tsaknis J. Chios mastic gum modulates serum biochemical parameters in a human population. J Ethnopharmacol. 2007 Apr 20;111(1):43-9. doi: 10.1016/j.jep.2006.10.031. Epub 2006 Nov 6.
- Kanoni S, Kumar S, Amerikanou C, Kurth MJ, Stathopoulou MG, Bourgeois S, Masson C, Kannt A, Cesarini L, Kontoe MS, Milanovic M, Roig FJ, Beribaka M, Campolo J, Jimenez-Hernandez N, Milosevic N, Llorens C, Smyrnioudis I, Francino MP, Milic N, Kaliora AC, Trivella MG, Ruddock MW, Medic-Stojanoska M, Gastaldelli A, Lamont J, Deloukas P, Dedoussis GV, Visvikis-Siest S. Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-Inflammatory Status in Mastiha-Supplemented Patients With NAFLD. Front Immunol. 2021 May 7;12:683028. doi: 10.3389/fimmu.2021.683028. eCollection 2021.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 8, 2017
Primary Completion (ACTUAL)
June 8, 2019
Study Completion (ACTUAL)
June 8, 2019
Study Registration Dates
First Submitted
March 9, 2017
First Submitted That Met QC Criteria
April 26, 2017
First Posted (ACTUAL)
May 1, 2017
Study Record Updates
Last Update Posted (ACTUAL)
April 7, 2022
Last Update Submitted That Met QC Criteria
April 6, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MAST4HEALTH (691042)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Alcoholic Fatty Liver Disease
-
Naga P. ChalasaniDSM Nutritional Products, Inc.CompletedNon-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Non-Alcoholic Fatty LiverUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
Better TherapeuticsArizona Liver HealthCompletedNon-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty LiverUnited States
-
Puerta de Hierro University HospitalHospital Universitario Marqués de ValdecillaNot yet recruitingNon-Alcoholic Fatty Liver Disease | Non Alcoholic SteatohepatitisSpain
-
BASF ASUnknownNASH - Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver Disease | Non Alcoholic Fatty LiverUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
Clinical Trials on Mastiha
-
Harokopio UniversityRecruiting
-
Harokopio UniversityCompleted
-
Harokopio UniversityCompletedInflammatory Bowel DiseasesGreece
-
Harokopio UniversityCompleted
-
Harokopio UniversityCompletedBiological AvailabilityGreece
-
AHEPA University HospitalSkylitseio General Hospital of ChiosCompletedHypercholesterolemia | HyperlipidemiasGreece